Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era emerging humoral and cellular players. (PubMed, Haematologica) - Nov 27, 2025 - "Collectively, these findings highlight a need to study anti-HCMV immune protection beyond type-1 T cells and refine risk stratification models in alloSCT patients by inclusion of novel immune markers such as γδ T-cell frequencies and phenotypes. Leveraging the extended B-cell reconstitution window created by letermovir, novel immunotherapies (e.g., therapeutic antibodies) and future vaccines might boost humoral anti-HCMV immunity and benefit from synergisms with γδ T cells and "memory-like" NK cells in improving HCMV control."
IO biomarker • Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
Benedikt Weißbrich; Carolin Köchel; Chris D Lauruschkat; Hannah Görge; Hartmut Hengel; Hermann Einsele; Kerstin Knies; Lars Dölken; Magdalena Huber; Nina Imhof; Sabrina Kraus; Sebastian Wurster
|